Compare TNON & CELZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNON | CELZ |
|---|---|---|
| Founded | 2012 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8M | 4.6M |
| IPO Year | 2021 | 2008 |
| Metric | TNON | CELZ |
|---|---|---|
| Price | $0.91 | $0.41 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 95.4K | 79.0K |
| Earning Date | 11-12-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 84.90 | 32.08 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,944,000.00 | $6,000.00 |
| Revenue This Year | $44.38 | N/A |
| Revenue Next Year | $39.49 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 20.35 | N/A |
| 52 Week Low | $0.96 | $0.44 |
| 52 Week High | $40.95 | $4.72 |
| Indicator | TNON | CELZ |
|---|---|---|
| Relative Strength Index (RSI) | 22.15 | 22.17 |
| Support Level | N/A | N/A |
| Resistance Level | $4.18 | $2.39 |
| Average True Range (ATR) | 0.17 | 0.05 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 4.65 | 0.95 |
Tenon Medical Inc is a medical device company that has minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.